PDF herunterladen
Semin Thromb Hemost 2015; 41(07): 747-755
DOI: 10.1055/s-0035-1556048
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Tissue Factor: Old and New Links with Cancer Biology

Henri H. Versteeg
1   Department of Internal Medicine/Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
26. September 2015 (online)

    Lizenzen und Reprints

Abstract

Blood coagulation is one of the most profound factors that influence cancer progression. Especially the initiator of coagulation, tissue factor (TF), has been subject to many studies investigating the overlap between coagulation and cancer. It has been known for decades that TF is a risk factor for metastasis, and in mouse models, TF drives metastasis in a coagulation-dependent manner. However, TF also serves as a cellular receptor to drive primary tumor growth and tumor angiogenesis. Nevertheless, recent studies have indicated that TF plays more fundamental roles in cancer biology. TF regulates tumor cell dormancy, is associated with cancer stem cell behavior, epithelial-to-mesenchymal transition, and dictates establishment of the tumor cell premetastatic niche. Especially with regard to these recent roles attributed to TF, no clear idea exists on the exact molecular pathways that are initiated by TF. Finally, TF alternative splicing results in an isoform with different characteristics and functions in cancer. In this review, a summary will be given on both the established as well as the new aspects of TF function in cancer progression.

Keywords

blood clotting - integrins - tumor biology - stem cells - protease-activated receptors
 

  • References

  • 1 Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood 2013; 122 (10) 1712-1723
    CrossrefPubMedGoogle Scholar
  • 2 Lyman GH, Khorana AA. Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol 2009; 27 (29) 4821-4826
    CrossrefPubMedGoogle Scholar
  • 3 Klerk CPW, Smorenburg SM, Otten H-M , et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23 (10) 2130-2135
    CrossrefPubMedGoogle Scholar
  • 4 Lee AYY, Rickles FR, Julian JA , et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23 (10) 2123-2129
    Google Scholar
  • 5 Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of anticoagulation trial. N Engl J Med 2000; 342 (26) 1953-1958
    CrossrefPubMedGoogle Scholar
  • 6 Pengo V, Noventa F, Denas G , et al. Long-term use of vitamin K antagonists and incidence of cancer: a population-based study. Blood 2011; 117 (5) 1707-1709
    CrossrefPubMedGoogle Scholar
  • 7 van den Berg YW, Osanto S, Reitsma PH, Versteeg HH. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood 2012; 119 (4) 924-932
    CrossrefPubMedGoogle Scholar
  • 8 Versteeg HH, Heemskerk JWM, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiol Rev 2013; 93 (1) 327-358
    CrossrefPubMedGoogle Scholar
  • 9 Ünlü B, Versteeg HH. Effects of tumor-expressed coagulation factors on cancer progression and venous thrombosis: is there a key factor?. Thromb Res 2014; 133 (Suppl. 02) S76-S84
    PubMedGoogle Scholar
  • 10 Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64 (6) 1057-1068
    CrossrefPubMedGoogle Scholar
  • 11 Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296 (5574) 1880-1882
    CrossrefPubMedGoogle Scholar
  • 12 Nakanishi-Matsui M, Zheng YW, Sulciner DJ, Weiss EJ, Ludeman MJ, Coughlin SR. PAR3 is a cofactor for PAR4 activation by thrombin. Nature 2000; 404 (6778) 609-613
    CrossrefPubMedGoogle Scholar
  • 13 Bretschneider E, Spanbroek R, Lötzer K, Habenicht AJR, Schrör K. Evidence for functionally active protease-activated receptor-3 (PAR-3) in human vascular smooth muscle cells. Thromb Haemost 2003; 90 (4) 704-709
    PubMedGoogle Scholar
  • 14 Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci U S A 1990; 87 (18) 6934-6938
    CrossrefPubMedGoogle Scholar
  • 15 Camerer E, Huang W, Coughlin SR. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci U S A 2000; 97 (10) 5255-5260
    CrossrefPubMedGoogle Scholar
  • 16 Camerer E, Rottingen JA, Iversen JG, Prydz H. Coagulation factors VII and X induce Ca2+ oscillations in Madin-Darby canine kidney cells only when proteolytically active. J Biol Chem 1996; 271 (46) 29034-29042
    CrossrefPubMedGoogle Scholar
  • 17 Versteeg HH, Hoedemaeker I, Diks SH , et al. Factor VIIa/tissue factor-induced signaling via activation of Src-like kinases, phosphatidylinositol 3-kinase, and Rac. J Biol Chem 2000; 275 (37) 28750-28756
    CrossrefPubMedGoogle Scholar
  • 18 Versteeg HH, Bresser HL, Spek CA, Richel DJ, Van Deventer SJ, Peppelenbosch MP. Regulation of the p21Ras-MAP kinase pathway by factor VIIa. J Thromb Haemost 2003; 1 (5) 1012-1018
    CrossrefPubMedGoogle Scholar
  • 19 Camerer E, Gjernes E, Wiiger M, Pringle S, Prydz H. Binding of factor VIIa to tissue factor on keratinocytes induces gene expression. J Biol Chem 2000; 275 (9) 6580-6585
    CrossrefPubMedGoogle Scholar
  • 20 Versteeg HH, Sørensen BB, Slofstra SH , et al. VIIa/tissue factor interaction results in a tissue factor cytoplasmic domain-independent activation of protein synthesis, p70, and p90 S6 kinase phosphorylation. J Biol Chem 2002; 277 (30) 27065-27072
    CrossrefPubMedGoogle Scholar
  • 21 Versteeg HH, Spek CA, Richel DJ, Peppelenbosch MP. Coagulation factors VIIa and Xa inhibit apoptosis and anoikis. Oncogene 2004; 23 (2) 410-417
    CrossrefPubMedGoogle Scholar
  • 22 Ahamed J, Versteeg HH, Kerver M , et al. Disulfide isomerization switches tissue factor from coagulation to cell signaling. Proc Natl Acad Sci U S A 2006; 103 (38) 13932-13937
    CrossrefPubMedGoogle Scholar
  • 23 Reinhardt C, von Brühl M-L, Manukyan D , et al. Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation. J Clin Invest 2008; 118 (3) 1110-1122
    PubMedGoogle Scholar
  • 24 Versteeg HH, Schaffner F, Kerver M , et al. Inhibition of tissue factor signaling suppresses tumor growth. Blood 2008; 111 (1) 190-199
    CrossrefPubMedGoogle Scholar
  • 25 Dorfleutner A, Hintermann E, Tarui T, Takada Y, Ruf W. Cross-talk of integrin alpha3beta1 and tissue factor in cell migration. Mol Biol Cell 2004; 15 (10) 4416-4425
    CrossrefPubMedGoogle Scholar
  • 26 Belting M, Dorrell MI, Sandgren S , et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004; 10 (5) 502-509
    Google Scholar
  • 27 Collier MEW, Ettelaie C. Induction of endothelial cell proliferation by recombinant and microparticle-tissue factor involves beta1-integrin and extracellular signal regulated kinase activation. Arterioscler Thromb Vasc Biol 2010; 30 (9) 1810-1817
    CrossrefPubMedGoogle Scholar
  • 28 Collier MEW, Li C, Ettelaie C. Influence of exogenous tissue factor on estrogen receptor alpha expression in breast cancer cells: involvement of beta1-integrin, PAR2, and mitogen-activated protein kinase activation. Mol Cancer Res 2008; 6 (12) 1807-1818
    CrossrefPubMedGoogle Scholar
  • 29 Arderiu G, Peña E, Aledo R, Juan-Babot O, Badimon L. Tissue factor regulates microvessel formation and stabilization by induction of chemokine (C-C motif) ligand 2 expression. Arterioscler Thromb Vasc Biol 2011; 31 (11) 2607-2615
    CrossrefPubMedGoogle Scholar
  • 30 Arderiu G, Peña E, Aledo R, Badimon L. Tissue factor-Akt signaling triggers microvessel formation. J Thromb Haemost 2012; 10 (9) 1895-1905
    CrossrefPubMedGoogle Scholar
  • 31 Yu JL, May L, Lhotak V , et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005; 105 (4) 1734-1741
    CrossrefPubMedGoogle Scholar
  • 32 Magnus N, Garnier D, Rak J. Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. Blood 2010; 116 (5) 815-818
    CrossrefPubMedGoogle Scholar
  • 33 Rong Y, Post DE, Pieper RO, Durden DL, Van Meir EG, Brat DJ. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 2005; 65 (4) 1406-1413
    CrossrefPubMedGoogle Scholar
  • 34 Sun L, Liu Y, Lin S , et al. Early growth response gene-1 and hypoxia-inducible factor-1α affect tumor metastasis via regulation of tissue factor. Acta Oncol 2013; 52 (4) 842-851
    CrossrefPubMedGoogle Scholar
  • 35 Gessler F, Voss V, Dützmann S, Seifert V, Gerlach R, Kögel D. Inhibition of tissue factor/protease-activated receptor-2 signaling limits proliferation, migration and invasion of malignant glioma cells. Neuroscience 2010; 165 (4) 1312-1322
    CrossrefPubMedGoogle Scholar
  • 36 Yokota N, Koizume S, Miyagi E , et al. Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells. Br J Cancer 2009; 101 (12) 2023-2029
    CrossrefPubMedGoogle Scholar
  • 37 Kakkar AK, Lemoine NR, Scully MF, Tebbutt S, Williamson RC. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 1995; 82 (8) 1101-1104
    CrossrefPubMedGoogle Scholar
  • 38 Rydén L, Grabau D, Schaffner F, Jönsson PE, Ruf W, Belting M. Evidence for tissue factor phosphorylation and its correlation with protease-activated receptor expression and the prognosis of primary breast cancer. Int J Cancer 2010; 126 (10) 2330-2340
    PubMedGoogle Scholar
  • 39 Shigemori C, Wada H, Matsumoto K, Shiku H, Nakamura S, Suzuki H. Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost 1998; 80 (6) 894-898
    PubMedGoogle Scholar
  • 40 Kocatürk B, Van den Berg YW, Tieken C , et al. Alternatively spliced tissue factor promotes breast cancer growth in a β1 integrin-dependent manner. Proc Natl Acad Sci U S A 2013; 110 (28) 11517-11522
    CrossrefPubMedGoogle Scholar
  • 41 Yeh H-H, Chang W-T, Lu K-C, Lai WW, Liu HS, Su WC. Upregulation of tissue factor by activated Stat3 contributes to malignant pleural effusion generation via enhancing tumor metastasis and vascular permeability in lung adenocarcinoma. PLoS ONE 2013; 8 (9) e75287
    CrossrefPubMedGoogle Scholar
  • 42 Song HB, Park KD, Kim JH, Kim DH, Yu YS, Kim JH. Tissue factor regulates tumor angiogenesis of retinoblastoma via the extracellular signal-regulated kinase pathway. Oncol Rep 2012; 28 (6) 2057-2062
    PubMedGoogle Scholar
  • 43 Zhang Y, Deng Y, Luther T , et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994; 94 (3) 1320-1327
    Google Scholar
  • 44 Versteeg HH, Spek CA, Slofstra SH, Diks SH, Richel DJ, Peppelenbosch MP. FVIIa:TF induces cell survival via G12/G13-dependent Jak/STAT activation and BclXL production. Circ Res 2004; 94 (8) 1032-1040
    CrossrefPubMedGoogle Scholar
  • 45 Abe K, Shoji M, Chen J , et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci U S A 1999; 96 (15) 8663-8668
    CrossrefPubMedGoogle Scholar
  • 46 Versteeg HH, Schaffner F, Kerver M , et al. Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice. Cancer Res 2008; 68 (17) 7219-7227
    CrossrefPubMedGoogle Scholar
  • 47 Milsom CC, Yu JL, Mackman N , et al. Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis. Cancer Res 2008; 68 (24) 10068-10076
    CrossrefPubMedGoogle Scholar
  • 48 Saito Y, Hashimoto Y, Kuroda J , et al. The inhibition of pancreatic cancer invasion-metastasis cascade in both cellular signal and blood coagulation cascade of tissue factor by its neutralisation antibody. Eur J Cancer 2011; 47 (14) 2230-2239
    CrossrefPubMedGoogle Scholar
  • 49 Schaffner F, Versteeg HH, Schillert A , et al. Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development. Blood 2010; 116 (26) 6106-6113
    CrossrefPubMedGoogle Scholar
  • 50 Yu J, May L, Milsom C , et al. Contribution of host-derived tissue factor to tumor neovascularization. Arterioscler Thromb Vasc Biol 2008; 28 (11) 1975-1981
    CrossrefPubMedGoogle Scholar
  • 51 Zhang J-Q, Wan Y-L, Liu Y-C , et al. The FVIIa-tissue factor complex induces the expression of MMP7 in LOVO cells in vitro. Int J Colorectal Dis 2008; 23 (10) 971-978
    CrossrefPubMedGoogle Scholar
  • 52 Lin Z-M, Zhao J-X, Duan X-N , et al. Effects of tissue factor, PAR-2 and MMP-9 expression on human breast cancer cell line MCF-7 invasion. Asian Pac J Cancer Prev 2014; 15 (2) 643-646
    CrossrefPubMedGoogle Scholar
  • 53 Tian M, Wan Y, Tang J , et al. Depletion of tissue factor suppresses hepatic metastasis and tumor growth in colorectal cancer via the downregulation of MMPs and the induction of autophagy and apoptosis. Cancer Biol Ther 2011; 12 (10) 896-907
    CrossrefPubMedGoogle Scholar
  • 54 Conn EM, Madsen MA, Cravatt BF, Ruf W, Deryugina EI, Quigley JP. Cell surface proteomics identifies molecules functionally linked to tumor cell intravasation. J Biol Chem 2008; 283 (39) 26518-26527
    CrossrefPubMedGoogle Scholar
  • 55 Morris DR, Ding Y, Ricks TK, Gullapalli A, Wolfe BL, Trejo J. Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Res 2006; 66 (1) 307-314
    CrossrefPubMedGoogle Scholar
  • 56 Fischer EG, Riewald M, Huang HY , et al. Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor. J Clin Invest 1999; 104 (9) 1213-1221
    Google Scholar
  • 57 Seto S, Onodera H, Kaido T , et al. Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis. Cancer 2000; 88 (2) 295-301
    CrossrefPubMedGoogle Scholar
  • 58 Palumbo JS, Talmage KE, Massari JV , et al. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood 2007; 110 (1) 133-141
    CrossrefPubMedGoogle Scholar
  • 59 Brüggemann LW, Versteeg HH, Niers TM, Reitsma PH, Spek CA. Experimental melanoma metastasis in lungs of mice with congenital coagulation disorders. J Cell Mol Med 2008; 12 (6B): 2622-2627
    CrossrefPubMedGoogle Scholar
  • 60 Palumbo JS, Talmage KE, Massari JV , et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005; 105 (1) 178-185
    CrossrefPubMedGoogle Scholar
  • 61 Gil-Bernabé AM, Ferjancic S, Tlalka M , et al. Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood 2012; 119 (13) 3164-3175
    CrossrefPubMedGoogle Scholar
  • 62 Findlay VJ, Wang C, Watson DK, Camp ER. Epithelial-to-mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer. Cancer Gene Ther 2014; 21 (5) 181-187
    CrossrefPubMedGoogle Scholar
  • 63 Mallini P, Lennard T, Kirby J, Meeson A. Epithelial-to-mesenchymal transition: what is the impact on breast cancer stem cells and drug resistance. Cancer Treat Rev 2014; 40 (3) 341-348
    CrossrefPubMedGoogle Scholar
  • 64 Milsom C, Anderson GM, Weitz JI, Rak J. Elevated tissue factor procoagulant activity in CD133-positive cancer cells. J Thromb Haemost 2007; 5 (12) 2550-2552
    CrossrefPubMedGoogle Scholar
  • 65 Magnus N, Garnier D, Meehan B , et al. Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations. Proc Natl Acad Sci U S A 2014; 111 (9) 3544-3549
    CrossrefPubMedGoogle Scholar
  • 66 Peña E, Arderiu G, Badimon L. Tissue factor induces human coronary artery smooth muscle cell motility through Wnt-signalling. J Thromb Haemost 2013; 11 (10) 1880-1891
    PubMedGoogle Scholar
  • 67 Schaffner F, Yokota N, Carneiro-Lobo T , et al. Endothelial protein C receptor function in murine and human breast cancer development. PLoS ONE 2013; 8 (4) e61071
    CrossrefPubMedGoogle Scholar
  • 68 Slatter TL, Hung N, Campbell H , et al. Hyperproliferation, cancer, and inflammation in mice expressing a Δ133p53-like isoform. Blood 2011; 117 (19) 5166-5177
    CrossrefPubMedGoogle Scholar
  • 69 Pabla N, Bhatt K, Dong Z. Checkpoint kinase 1 (Chk1)-short is a splice variant and endogenous inhibitor of Chk1 that regulates cell cycle and DNA damage checkpoints. Proc Natl Acad Sci U S A 2012; 109 (1) 197-202
    CrossrefPubMedGoogle Scholar
  • 70 Nowak DG, Woolard J, Amin EM , et al. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci 2008; 121 (Pt 20) 3487-3495
    CrossrefPubMedGoogle Scholar
  • 71 Cáceres JF, Kornblihtt AR. Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet 2002; 18 (4) 186-193
    CrossrefPubMedGoogle Scholar
  • 72 Chandradas S, Deikus G, Tardos JG, Bogdanov VY. Antagonistic roles of four SR proteins in the biosynthesis of alternatively spliced tissue factor transcripts in monocytic cells. J Leukoc Biol 2010; 87 (1) 147-152
    CrossrefPubMedGoogle Scholar
  • 73 Eisenreich A, Bogdanov VY, Zakrzewicz A , et al. Cdc2-like kinases and DNA topoisomerase I regulate alternative splicing of tissue factor in human endothelial cells. Circ Res 2009; 104 (5) 589-599
    CrossrefPubMedGoogle Scholar
  • 74 Eisenreich A, Malz R, Pepke W , et al. Role of the phosphatidylinositol 3-kinase/protein kinase B pathway in regulating alternative splicing of tissue factor mRNA in human endothelial cells. Circ J 2009; 73 (9) 1746-1752
    CrossrefPubMedGoogle Scholar
  • 75 Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003; 9 (4) 458-462
    Google Scholar
  • 76 Rollin J, Regina S, Gruel Y. Tumor expression of alternatively spliced tissue factor is a prognostic marker in non-small cell lung cancer. J Thromb Haemost 2010; 8 (3) 607-610
    CrossrefPubMedGoogle Scholar
  • 77 Unruh D, Turner K, Srinivasan R , et al. Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma. Int J Cancer 2014; 134 (1) 9-20
    CrossrefPubMedGoogle Scholar
  • 78 van den Berg YW, van den Hengel LG, Myers HR , et al. Alternatively spliced tissue factor induces angiogenesis through integrin ligation. Proc Natl Acad Sci U S A 2009; 106 (46) 19497-19502
    CrossrefPubMedGoogle Scholar